RIGEL PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2017 | FY2016 |
|---|---|---|
| Revenue | $4.5M | $20.4M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | $37.8M | $20.9M |
| Operating Income | $-79.6M | $-69.7M |
| Operating Margin | -1,775.6% | -342.2% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | $0 | $0 |
| Net Income | $-78.0M | $-69.2M |
| Net Margin | -1,739.3% | -339.6% |
| EPS (Basic) | $-0.62 | $-0.73 |
| EPS (Diluted) | $-0.62 | $-0.73 |
| Shares Outstanding (Basic) | 146.8M | 99.3M |
| Shares Outstanding (Diluted) | 146.8M | 99.3M |
| Dividends Per Share | — | — |